In a move that could bring relief to millions of patients, the National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 drug formulations used to treat conditions such as diabetes, high blood pressure, heart disease, infections and women's health issues.
The decision is expected to help reduce treatment costs, particularly for people who rely on long-term medication to manage chronic illnesses.
Which Medicines Are Included In The Latest NPPA Price Fixation?
The latest notification covers a wide range of commonly prescribed medicines across several therapeutic categories.
These include:
- Anti-diabetic medicines containing empagliflozin, sitagliptin, metformin, teneligliptin and dapagliflozin
- Heart and blood pressure medicines containing atorvastatin, telmisartan, cilnidipine and metoprolol
- Antibiotics used to treat infections
- Pain-relief medicines
- Vitamin and calcium supplements
- Medicines used for women's health conditions
The revised prices set the maximum rate at which manufacturers can sell these formulations, excluding GST.
Key Diabetes And Heart Medicines Get New Prices
Among the notable formulations included in the notification are several medicines widely prescribed for diabetes and cardiovascular conditions.
Some of the newly fixed prices are:
- Empagliflozin, sitagliptin and metformin tablets: Rs 14.88 per tablet
- Sitagliptin, glimepiride and metformin tablets: Rs 11.91 per tablet
- Teneligliptin and dapagliflozin tablets: Rs 10.17 per tablet
- Atorvastatin and fenofibrate tablets: Rs 18.46 per tablet
Meanwhile, Tacrolimus capsules, which are commonly used by organ transplant patients, have been priced at Rs 127 per capsule.
Children's Medicines And Women's Health Drugs Also Covered
The NPPA's latest list extends beyond chronic disease treatment.
Several other formulations included in the notification are:
- Cefpodoxime-clavulanate antibiotic suspensions for children
- Vitamin D3 oral solutions
- Calcium and vitamin supplements
- Norethisterone acetate tablets used in women's health treatment
The move is expected to improve affordability across multiple healthcare categories.
When Will Patients See The Benefit?
According to industry representatives, patients may start seeing the impact of the revised prices within the next two to three months.
Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists, welcomed the decision and said consumers are likely to benefit once older stock already present in the supply chain is cleared.
The revised-price medicines are expected to reach pharmacies gradually over the next 60 to 90 days.
Why Affordable Medicines Matter
Health experts point out that medicines make up a significant portion of healthcare spending for Indian households, especially for people living with chronic conditions such as diabetes, hypertension and heart disease.
Since many of these illnesses require lifelong treatment, even small reductions in medicine costs can help families manage their healthcare expenses more effectively.
Affordable medicines are also seen as crucial for ensuring that patients continue their prescribed treatment without interruption, leading to better long-term health outcomes.
What The NPPA's Latest Move Means For Patients
With prices now fixed for 30 commonly used drug formulations, the NPPA's latest decision could help improve access to essential medicines for millions of Indians.
For patients managing chronic diseases, lower medicine costs may ease financial pressure while supporting consistent treatment and better health management over time.
Inputs from TOI
